RESWAS SF SYRUP 120 ML

Reswas SF Syrup 120 ml is a cough medicine used to relieve cough. It helps to thin mucus and clear airways.

Reswas SF Syrup 120 ml is used to treat cough, sore throat, and other conditions caused by respiratory infections.

Common side effects of Reswas SF Syrup 120 ml include nausea, vomiting, diarrhea, and stomach pain.

The dosage of Reswas SF Syrup 120 ml is determined by the doctor. Typically, the dose for adults is 10 ml three times a day.

It is important to consult a doctor about whether Reswas SF Syrup 120 ml is safe for children.

Store Reswas SF Syrup 120 ml at room temperature, away from direct sunlight and heat.

If you miss a dose of Reswas SF Syrup 120 ml, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take the next dose.

Reswas SF Syrup 120 ml may interact with other medications. Therefore, it is important to tell your doctor about all your medications.

It is important to consult a doctor about the safety of Reswas SF Syrup 120 ml for pregnant women.

It is important to consult a doctor about the safety of Reswas SF Syrup 120 ml for breastfeeding women.

Reswas SF Syrup 120 ml may cause drowsiness in some people. Avoid driving or operating machinery if you experience drowsiness.

The active ingredients in Reswas SF Syrup 120 ml are Ambroxol and Guaifenesin.

Drinking alcohol with Reswas SF Syrup 120 ml may increase the risk of side effects. Consult a doctor before consuming alcohol.

Overdosing on Reswas SF Syrup 120 ml can cause side effects such as nausea, vomiting, diarrhea, and stomach pain. Seek immediate medical attention if you suspect an overdose.

Check with your local pharmacist or doctor to get information about the availability of Reswas SF Syrup 120 ml.

Reswas SF syrup is a combination cough preparation containing levodropropizine, a peripherally acting antitussive, and chlorpheniramine maleate, an antihistamine. It is generally used for short‑term symptomatic relief of dry, irritating, or non‑productive cough, especially when cough is associated with allergic symptoms such as sneezing or runny nose. It does not treat the underlying cause of cough and should be used only under medical supervision.

Levodropropizine reduces the sensitivity of peripheral sensory nerves in the airways that trigger the cough reflex. By acting mainly at the level of the respiratory tract rather than the central nervous system, it helps decrease the frequency and intensity of dry cough without the degree of sedation or respiratory depression associated with some centrally acting antitussives. It is intended for non‑productive cough where suppression is clinically appropriate.

Chlorpheniramine maleate is a first‑generation H1 antihistamine. In Reswas SF, it helps relieve symptoms related to allergic or irritative components of respiratory illness, such as sneezing, rhinorrhea (runny nose), and nasal or throat itching. Because it crosses the blood–brain barrier, it can cause sedation and impaired alertness in some individuals, which must be considered when performing tasks that require concentration.

Reswas SF is primarily intended for dry, non‑productive cough. In productive cough, suppression of the cough reflex may hinder clearance of mucus from the airways and could potentially worsen the underlying condition. Therefore, it should not be used for productive cough unless a physician specifically decides that temporary cough suppression is necessary and safe in the individual clinical context.

Use of Reswas SF in children must follow a physician’s explicit recommendation. Age and body weight restrictions, as well as dosing intervals, are defined in the approved product information and vary by country and formulation. Antitussives and first‑generation antihistamines require particular caution in young children because of the risk of excessive sedation, paradoxical excitation, breathing difficulties, and dosing errors. Caregivers should never give Reswas SF to a child without medical advice.

Commonly reported side effects include drowsiness, dizziness, fatigue, dry mouth, mild gastrointestinal symptoms such as nausea, abdominal discomfort, or diarrhea, and occasionally headache. Chlorpheniramine may also cause blurred vision or difficulty concentrating. Most adverse effects are mild and reversible after discontinuation. If severe drowsiness, breathing difficulty, palpitations, rash, or swelling of the face or throat occurs, medical attention is required immediately.

Caution is required when combining Reswas SF with other cold or allergy products, especially those that contain sedating antihistamines, decongestants, or additional cough suppressants. Concomitant use can increase the risk of side effects such as excessive drowsiness, dry mouth, urinary retention, or cardiovascular effects. Patients should consult a doctor or pharmacist before using Reswas SF alongside any other over‑the‑counter or prescription cold, cough, or allergy medication.

Yes, Reswas SF can cause drowsiness, dizziness, and reduced alertness, mainly due to chlorpheniramine. Individual sensitivity varies, but some patients may experience significant impairment in reaction time and concentration. Until a patient knows how they respond to the medicine, they should avoid driving, operating machinery, or performing tasks that require full mental alertness. If marked sedation occurs, they should contact their healthcare provider.

Use of Reswas SF during pregnancy or breastfeeding is not routinely recommended and should occur only if a physician judges that the potential benefit outweighs possible risks. Data on levodropropizine in pregnancy and lactation are limited, and chlorpheniramine crosses the placenta and is excreted in breast milk. Pregnant or breastfeeding individuals should consult their healthcare provider for an individualized assessment and should not self‑medicate with Reswas SF.

If cough persists for more than a few days, worsens, or is accompanied by high fever, chest pain, difficulty breathing, blood in sputum, or unexplained weight loss, the medicine should not simply be continued without review. Persistent cough may indicate a more serious underlying condition that requires diagnostic evaluation. Patients should stop self‑medication and seek prompt medical assessment to determine the cause and appropriate treatment.

Reswas SF is generally contraindicated or used with great caution in individuals with known hypersensitivity to levodropropizine, chlorpheniramine, or any excipients in the formulation; in patients with severe respiratory failure where cough suppression could be harmful; and in certain conditions where first‑generation antihistamines are not advisable, such as narrow‑angle glaucoma, significant urinary retention, or severe prostatic hypertrophy. Patients with liver or kidney impairment, cardiovascular disease, or chronic respiratory disease should use it only under close medical supervision.